| N a | MAFb | Association test | |||
---|---|---|---|---|---|---|
Study | Cases | Controls | Cases | Controls | OR (95% CI) | p-value |
CD2AP- rs9349407-C (minor) allele | ||||||
ADGC Discovery (Stage 1) | 8,309 | 7,366 |  |  | 1.14 (1.08-1.21) | 1.2 × 10 -6 |
ADGC Replication (Stage 2) | 3,531 | 3,565 | Â | Â | 1.07 (0.98-1.17) | 0.12 |
ADGC combined analysis (Stages 1+2) | 11,840 | 10,931 |  |  | 1.12 (1.07-1.18) | 1.0 × 10 -6 |
Hollingworth et al. (GERAD + Consortia) | 6,283 | 7,165 |  |  | 1.11 (1.04-1.18) | 8 × 10 -4 |
Mayo2c | 2,521 | 4,055 | 0.27 | 0.27 | 0.97 (0.89-1.07) | 0.56 |
Jacksonville | 492 | 922 | 0.28 | 0.26 | 1.10 (0.91-1.33) | 0.34 |
Rochester | 313 | 1,600 | 0.26 | 0.27 | 0.88 (0.70-1.09) | 0.24 |
Autopsy | 285 | 100 | 0.26 | 0.29 | 0.98 (0.65-1.47) | 0.92 |
Norway | 324 | 519 | 0.25 | 0.28 | 0.81 (0.62-1.06) | 0.13 |
Poland | 468 | 181 | 0.29 | 0.25 | 1.04 (0.77-1.42) | 0.79 |
ARUK | 639 | 733 | 0.28 | 0.29 | 0.97 (0.81-1.16) | 0.72 |
ADGC/Hollingworthd | 18,123 | 18,096 |  |  |  | 1.2 × 10-10 |
Mayo2/ADGC/Hollingworthe | 20,644 | 22,151 |  |  |  | 6.5 × 10-11 |
EPHA1- rs11767557-C (minor) allele | ||||||
ADGC Discovery (Stage 1) | 8,309 | 7,366 |  |  | 0.85 (0.80-0.90) | 7.3 × 10 -8 |
ADGC Replication (Stage 2) | 3,531 | 3,565 | Â | Â | 0.94 (0.86-1.03) | 0.17 |
ADGC combined analysis (Stages 1+2) | 11,840 | 10,931 |  |  | 0.87 (0.83-0.92) | 2.4 × 10 -7 |
Hollingworth et al (GERAD + Consortia) | 6,283 | 12,935 |  |  | 0.90 (0.85-0.95) | 3.4 × 10 -4 |
Mayo2c | 2,509 | 4,055 | 0.19 | 0.21 | 0.87 (0.78-0.96) | 5.5 × 10 -4 |
Jacksonville | 501 | 957 | 0.18 | 0.20 | 0.86 (0.70-1.06) | 0.17 |
Rochester | 309 | 1,572 | 0.19 | 0.21 | 0.89 (0.69-1.13) | 0.33 |
Autopsy | 307 | 99 | 0.17 | 0.24 | 0.66 (0.43-1.02) | 0.06 |
Norway | 338 | 548 | 0.21 | 0.22 | 0.94 (0.71-1.24) | 0.67 |
Poland | 457 | 169 | 0.20 | 0.21 | 0.93 (0.66-1.31) | 0.67 |
ARUK | 597 | 710 | 0.19 | 0.22 | 0.85 (0.69-1.04) | 0.12 |
ADGC/Hollingworthd | 18,123 | 18,096 |  |  |  | 4.2 × 10-12 |
Mayo2/ADGC/Hollingworthe | 20,632 | 27,921 |  |  |  | 2.1 × 10-15 |
ARID5B- rs2588969-A (minor) allele | ||||||
ADGC Discovery (Stage 1) | 8,309 | 7,366 |  |  | 0.88 (0.84-0.93) | 1.1 × 10 -6 |
ADGC Replication (Stage 2) | 3,531 | 3,565 | Â | Â | 1.05 (0.97-1.13) | 0.23 |
ADGC combined analysis (Stages 1+2) | 11,840 | 10,931 | Â | Â | 0.93 (0.89-0.97) | 0.001 |
Hollingworth et al (GERAD + Consortia) | 6,283 | 7,165 | Â | Â | 1.06 (1.01-1.13) | 0.03 |
Mayo2c | 2,571 | 4,102 | 0.40 | 0.38 | 1.05 (0.96-1.14) | 0.30 |
Jacksonville | 495 | 928 | 0.39 | 0.38 | 1.04 (0.88-1.23) | 0.63 |
Rochester | 307 | 1,604 | 0.42 | 0.38 | 1.12 (0.92-1.37) | 0.26 |
Autopsy | 308 | 102 | 0.38 | 0.32 | 1.24 (0.86-1.79) | 0.24 |
Norway | 338 | 543 | 0.37 | 0.37 | 1.05 (0.83-1.33) | 0.69 |
Poland | 473 | 185 | 0.42 | 0.40 | 0.91 (0.68-1.20) | 0.49 |
ARUK | 650 | 740 | 0.40 | 0.39 | 1.05 (0.88-1.24) | 0.61 |
ADGC/Hollingworthd | 18,123 | 18,096 |  |  |  | 7.6 × 10-9 |
Mayo2/ADGC/Hollingworthe | 20,694 | 22,198 |  |  |  | 2.3 × 10-9 |
ARID5B-rs4948288-A (minor) allele | ||||||
ADGC Discovery (Stage 1) | 8,309 | 7,366 | Â | Â | Â | Â |
ADGC Replication (Stage 2) | 3,531 | 3,565 | Â | Â | Â | Â |
ADGC combined analysis (Stages 1+2) | 11,840 | 10,931 | Â | Â | Â | Â |
Hollingworth et al (GERAD + Consortia) | 6,992 | 13,472 |  |  | 1.07 (1.03-1.15) | 3.6 × 10 -3 |
Mayo2c | 2,556 | 4,058 | 0.42 | 0.40 | 1.07 (0.99-1.16) | 0.11 |
Jacksonville | 496 | 925 | 0.43 | 0.39 | 1.13 (0.96-1.34) | 0.14 |
Rochester | 314 | 1,579 | 0.43 | 0.40 | 1.08 (0.89-1.32) | 0.43 |
Autopsy | 300 | 98 | 0.38 | 0.39 | 0.91 (0.63-1.32) | 0.61 |
Norway | 324 | 540 | 0.40 | 0.41 | 1.06 (0.83-1.34) | 0.64 |
Poland | 466 | 184 | 0.42 | 0.40 | 0.90 (0.68-1.20) | 0.48 |
ARUK | 656 | 732 | 0.43 | 0.41 | 1.13 (0.96-1.33) | 0.14 |
Mayo2/ADGC/Hollingworthe | 9,548 | 17,530 |  |  |  | 4.0 × 10-4 |
CD33 - rs3865444-A (minor) allele | ||||||
ADGC Discovery (Stage 1) | 8,309 | 7,366 |  |  | 0.88 (0.84-0.93) | 8.2 × 10 -7 |
ADGC Replication (Stage 2) | 3,531 | 3,565 | Â | Â | 0.91 (0.85-0.99) | 0.02 |
ADGC combined analysis (Stages 1+2) | 11,840 | 10,931 |  |  | 0.89 (0.86-0.93) | 1.1 × 10 -7 |
Hollingworth et al (GERAD + Consortia) | 6,283 | 7,165 |  |  | 0.89 (0.84-0.95) | 2.2 × 10 -4 |
Mayo2c | 2538 | 4052 | 0.31 | 0.32 | 0.92 (0.84-1.00) | 4.9 × 10 -2 |
Jacksonville | 492 | 920 | 0.29 | 0.31 | 0.82 (0.68-0.98) | 0.03 |
Rochester | 312 | 1,577 | 0.31 | 0.33 | 0.88 (0.72-1.08) | 0.23 |
Autopsy | 298 | 97 | 0.32 | 0.34 | 0.84 (0.57-1.24) | 0.39 |
Norway | 327 | 541 | 0.32 | 0.32 | 0.89 (0.70-1.14) | 0.37 |
Poland | 467 | 187 | 0.30 | 0.26 | 1.00 (0.72-1.37) | 0.99 |
ARUK | 642 | 730 | 0.33 | 0.34 | 0.98 (0.83-1.17) | 0.85 |
ADGC/Hollingworthd | 18,123 | 18,096 |  |  |  | 3.6 × 10-12 |
Mayo2/ADGC/Hollingworthe | 20,661 | 22,148 |  |  |  | 1.8 × 10-13 |